Seroprevalence of Babesia microti in Individuals with Lyme Disease
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Abstract

There is a higher co-infection rate of B. microti in individuals that test
positive for B. burgorferi than is currently being reported in New York State.
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Babesiosis is a tickborne disease caused by Babesia microti, an
intracellular parasite of red blood cells. Presently, B. microti is the most
common and deadly pathogen transmitted by blood transfusion. B.
microti infects humans via Ixodes scapularis ticks, the same vector that
carries Borrelia burgdorferi, the causative agent of Lyme disease. Coinfection with these two diseases increases the duration and severity of
symptoms, posing a major therapeutic challenge. We aimed to determine
the co-infection rate of B. microti in individuals who tested positive for
Lyme disease in New York State. Of the 154 sera samples that were
tested by immunofluorescence assay, 33 (21.4%) of the of the individuals
who had Lyme disease and a current B. burgdorferi infection also tested
positive for IgM and IgG antibodies against B. microti, suggesting recent
co-infection with both TBDs. Additionally, of the individuals who previously
had Lyme disease as indicated by IgG antibodies against B. burgdorferi,
4 (2.6%) tested positive for antibodies against B. microti. Only one
individual (0.7%) in the Lyme disease negative control group was positive
for antibodies against B. microti. The results suggests co-infection of B.
microti and Lyme disease is prevalent in New York, an area endemic for
TBDs. Additionally, our findings agree with reports that B. burgdorferi may
help facilitate the emergence of B. microti. Our data suggest the need for
an extensive study investigating co-infection of B. microti and Lyme
disease and further support the need for an FDA-approved screening test
to help prevent transfusion-transmitted babesiosis.

Hypothesis

Month
Figure 2. Sample population
and demographics. A. Sample collection. Breakdown of the months in which samples (n=154)
were collected. Samples were collected during summer months in which tickborne diseases are most prevalent. B. Gender
distribution. Of the individuals tested, 58% were male, 40% were female and 2% were unknown. C. Age distribution. The median
age of our sample population was 46.6 and our mean age was 52.
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Introduction
Human babesiosis is an emerging zoonotic TBD caused by protozoa of
the genus Babesia, which are obligate intracellular parasites of red blood
cells1. Babesia microti is currently the number one pathogen that is
transmitted by blood transfusion in the U.S. for which no FDA-approved
donor screening is currently available1. It is also responsible for the
highest percentage (38%) of transfusion-related infectious fatalities
reported to the FDA in transfusion recipients2.
B. microti and B. burgdorferi, the causative agents of human babesiosis
and Lyme disease respectively, are known to be prevalent within the same
geographical range3. This is attributed to the fact that the same vector, the
Ixodes scapularis tick, transmits both infections. I. scapularis ticks may be
infected with either of these pathogens or both simultaneously4. Some
studies have suggested concurrent infection with B. burgdorferi has a
synergistic effect on B. microti3.
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Figure 3. Indirect Immunofluorescence
assay for B. microti. Immunofluorescence
assay (IFA) was used for the detection of
IgM and IgG classes of antibodies against
B. microti in human sera.

Reported co-infection rates of B. microti with B. burgdorferi in varies
greatly with the focus often being on the co-infection of ticks and not
humans4,5. Moreover, it has been suggested that co-infection with these
two diseases, promotes the development of more severe symptoms than
seen in patients infected with the individual pathogen; which poses a
major therapeutic challenge6. In addition, each of these diseases are
treated with different antibiotic regimens, specific to that parasitic disorder.
If co-infection is not diagnosed in a patient, then only one of the diseases
may be successfully treated, posing a risk to immunocompromised
individuals undergoing blood transfusion.

Figure 4. Representative images of B. microti immunofluorescence assay. A
titer of 1:32 was used to determine whether an individual was positive for
antibodies against IgM, while a titer of 1:64 was used for IgG antibodies. A-D.
Representative images of the negative control (A), positive control (B), positive
individual at 1:32 dilution for IgM antibodies (C), and positive individual at 1:64
dilution for IgG antibodies.

Table 1. Results table. Presence of Lyme disease was based on the detection of IgM (current infection) or IgG (past infection)
antibodies or both by Western blotting. Individuals were considered IFA positive for B. microti if they tested positive for both IgM
and IgG antibodies. Of the 154 samples tested, 0.7% of patients tested negative for Lyme disease and positive for B. microti while
21.4% of patients were positive for current Lyme disease and B. microti, representing a significant increase for individuals with
current co-infection (p > 0.5). Of the individuals who previously had Lyme disease, 2.6% of patients were also positive for B.
microti.

Conclusions

Figure 1. Distribution of Reported Lyme and Lyme/Babesiosis Patients
(Source: Trends in Pathology). Map of the United States indicating counties in
which reported reported cases of Lyme disease and co-infection of Lyme and
babesiosis, respectively. Counties with three or more cases of Lyme disease but
fewer than three cases of babesiosis are depicted in green. Counties with three or
more cases of Lyme disease and three or more cases of babesiosis are depicted
in gray.
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The aim of this study was to determine the co-infection rate of B. microti in individuals that tested positive for Lyme
disease. Overall, the findings of our study suggest that additional testing for the prevalence of Babesia, in individuals
suspected of or diagnosed with Lyme disease needs to be performed, particularly in areas where it is endemic.
Moving forward, it would be useful to do a more extensive study with a larger sample size and well matched controls.
The results presented in this study coincide with our hypothesis suggesting that there is a higher rate of co-infection
than previously reported.
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